CRISPR THERAPEUTICS AG news, videos and press releases
For more news please use our advanced search feature.
CRISPR THERAPEUTICS AG - More news...
CRISPR THERAPEUTICS AG - More news...
- CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
- CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- CRISPR Therapeutics Announces $280 Million Registered Direct Offering
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
- CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
- CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Thinking about buying stock in Crispr Therapeutics, Ardelyx, ADC Therapeutics, Acurx Pharmaceuticals, or Sphere 3D?
- CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
- Thinking about trading options or stock in Palantir Technologies, SoFi Technologies, Broadcom, Truist Financial, or Crispr Therapeutics?
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
- CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
- CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors
- CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- CRISPR Therapeutics Announces Leadership Transition
- CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
- CRISPR Therapeutics Announces Departure of Board Member
- CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
- CRISPR Therapeutics Announces Transition of Chief Financial Officer
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences
